User:Mr. Ibrahem/Dostarlimab

Dostarlimab, sold under the brand name Jemperli, is a medication used to treat certain solid tumors such as endometrial cancer. Specifically it is used for mismatch repair deficient (dMMR) recurrent or advanced cancer. Benefits were seen in 44% of cases. It is given by gradual injection into a vein.

Common side effects include tiredness, nausea, diarrhea, and anemia. Other side effects may include joint pain, itching, rash, fever, and low thyroid. Severe side effect may include pneumonitis, colitis and hepatitis due to immune dysfunction. Use during pregnancy may harm the baby. It is a monoclonal antibody which blocks programmed death receptor-1 (PD-1), thus allowing the immune system to kill cancer cells.

Dostarlimab was approved for medical use in the United States and Europe in 2021. In the United States it costs about 11,400 USD per 500 mg as of 2022. In the United Kingdom this amount costs about £5,900.